Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure

Athanassios Argiris, Daniel J. Haraf, Merrill S. Kies, Everett E. Vokes

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. In consecutive clinical studies since 1986, we have developed multi-agent chemoradiotherapy regimens based on initial observations with the 5-fluorouracil (5-FU), hydroxyurea, and concomitant radiotherapy combination. Three consecutive multicenter phase H trials reported that the combination of 5-FU and hydroxyurea with either cisplatin or paclitaxel along with twice daily radiation therapy administered every other week is a highly effective regimen with local control rates that approach 90% and 3-year survival rates of approximately 60% in patients with stage IV disease. The vast majority of patients in these studies achieved anatomical organ preservation. A reversal of the historical pattern of failure was evident, with distant sites becoming the predominant site of failure in each trial. The paclitaxel-containing regimen was better tolerated than the cisplatin-containing regimen and was advanced to further clinical testing. The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease.

Original languageEnglish (US)
Pages (from-to)350-360
Number of pages11
JournalOncologist
Volume8
Issue number4
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Hydroxyurea
Chemoradiotherapy
Head and Neck Neoplasms
Fluorouracil
Radiotherapy
Organ Preservation
Induction Chemotherapy
Paclitaxel
Cisplatin
Therapeutics
Survival Rate
Drug Therapy
Survival

Keywords

  • 5-FU
  • Chemotherapy
  • Head and neck cancer
  • Hydroxyurea
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens : Reversing a pattern of failure. / Argiris, Athanassios; Haraf, Daniel J.; Kies, Merrill S.; Vokes, Everett E.

In: Oncologist, Vol. 8, No. 4, 2003, p. 350-360.

Research output: Contribution to journalArticle

Argiris, Athanassios ; Haraf, Daniel J. ; Kies, Merrill S. ; Vokes, Everett E. / Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens : Reversing a pattern of failure. In: Oncologist. 2003 ; Vol. 8, No. 4. pp. 350-360.
@article{ddeefd3ec5674a64996683b82cb175ca,
title = "Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens: Reversing a pattern of failure",
abstract = "Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. In consecutive clinical studies since 1986, we have developed multi-agent chemoradiotherapy regimens based on initial observations with the 5-fluorouracil (5-FU), hydroxyurea, and concomitant radiotherapy combination. Three consecutive multicenter phase H trials reported that the combination of 5-FU and hydroxyurea with either cisplatin or paclitaxel along with twice daily radiation therapy administered every other week is a highly effective regimen with local control rates that approach 90{\%} and 3-year survival rates of approximately 60{\%} in patients with stage IV disease. The vast majority of patients in these studies achieved anatomical organ preservation. A reversal of the historical pattern of failure was evident, with distant sites becoming the predominant site of failure in each trial. The paclitaxel-containing regimen was better tolerated than the cisplatin-containing regimen and was advanced to further clinical testing. The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease.",
keywords = "5-FU, Chemotherapy, Head and neck cancer, Hydroxyurea, Radiotherapy",
author = "Athanassios Argiris and Haraf, {Daniel J.} and Kies, {Merrill S.} and Vokes, {Everett E.}",
year = "2003",
doi = "10.1634/theoncologist.8-4-350",
language = "English (US)",
volume = "8",
pages = "350--360",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Intensive concurrent chemoradiotherapy for head and neck cancer with 5-fluorouracil- and hydroxyurea-based regimens

T2 - Reversing a pattern of failure

AU - Argiris, Athanassios

AU - Haraf, Daniel J.

AU - Kies, Merrill S.

AU - Vokes, Everett E.

PY - 2003

Y1 - 2003

N2 - Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. In consecutive clinical studies since 1986, we have developed multi-agent chemoradiotherapy regimens based on initial observations with the 5-fluorouracil (5-FU), hydroxyurea, and concomitant radiotherapy combination. Three consecutive multicenter phase H trials reported that the combination of 5-FU and hydroxyurea with either cisplatin or paclitaxel along with twice daily radiation therapy administered every other week is a highly effective regimen with local control rates that approach 90% and 3-year survival rates of approximately 60% in patients with stage IV disease. The vast majority of patients in these studies achieved anatomical organ preservation. A reversal of the historical pattern of failure was evident, with distant sites becoming the predominant site of failure in each trial. The paclitaxel-containing regimen was better tolerated than the cisplatin-containing regimen and was advanced to further clinical testing. The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease.

AB - Combined modality programs that were developed over the past two decades demonstrated that the nonsurgical therapy of locoregionally advanced head and neck cancer is feasible and produces survival outcomes that are at least comparable with surgery. The systemic therapy of head and neck cancer has gained momentum in recent years. Several randomized studies have shown that the concurrent administration of chemotherapy and radiation therapy is superior to radiation therapy alone. In consecutive clinical studies since 1986, we have developed multi-agent chemoradiotherapy regimens based on initial observations with the 5-fluorouracil (5-FU), hydroxyurea, and concomitant radiotherapy combination. Three consecutive multicenter phase H trials reported that the combination of 5-FU and hydroxyurea with either cisplatin or paclitaxel along with twice daily radiation therapy administered every other week is a highly effective regimen with local control rates that approach 90% and 3-year survival rates of approximately 60% in patients with stage IV disease. The vast majority of patients in these studies achieved anatomical organ preservation. A reversal of the historical pattern of failure was evident, with distant sites becoming the predominant site of failure in each trial. The paclitaxel-containing regimen was better tolerated than the cisplatin-containing regimen and was advanced to further clinical testing. The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease.

KW - 5-FU

KW - Chemotherapy

KW - Head and neck cancer

KW - Hydroxyurea

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0041707983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041707983&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.8-4-350

DO - 10.1634/theoncologist.8-4-350

M3 - Article

C2 - 12897332

AN - SCOPUS:0041707983

VL - 8

SP - 350

EP - 360

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -